Teachers Advisors LLC raised its position in shares of BioScrip, Inc. (NASDAQ:BIOS) by 10.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 219,040 shares of the company’s stock after purchasing an additional 20,290 shares during the period. Teachers Advisors LLC owned 0.18% of BioScrip worth $595,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its holdings in BioScrip by 65.8% during the first quarter. Goldman Sachs Group Inc. now owns 64,257 shares of the company’s stock valued at $109,000 after purchasing an additional 25,500 shares during the period. American International Group Inc. grew its holdings in BioScrip by 73.8% during the first quarter. American International Group Inc. now owns 67,812 shares of the company’s stock valued at $115,000 after purchasing an additional 28,787 shares during the period. Wells Fargo & Company MN grew its holdings in BioScrip by 1.1% during the first quarter. Wells Fargo & Company MN now owns 113,710 shares of the company’s stock valued at $193,000 after purchasing an additional 1,254 shares during the period. Sheets Smith Wealth Management grew its holdings in BioScrip by 13.4% during the second quarter. Sheets Smith Wealth Management now owns 125,328 shares of the company’s stock valued at $340,000 after purchasing an additional 14,820 shares during the period. Finally, Rhumbline Advisers grew its holdings in BioScrip by 9.2% during the second quarter. Rhumbline Advisers now owns 130,122 shares of the company’s stock valued at $353,000 after purchasing an additional 10,985 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

In other news, Director Michael G. Bronfein sold 27,000 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $2.69, for a total value of $72,630.00. Following the completion of the transaction, the director now directly owns 129,669 shares of the company’s stock, valued at $348,809.61. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Coliseum Capital Management, L sold 2,846,941 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $2.93, for a total value of $8,341,537.13. The disclosure for this sale can be found here. Insiders sold 3,760,419 shares of company stock valued at $11,144,519 over the last ninety days. Corporate insiders own 0.80% of the company’s stock.

Several equities analysts have weighed in on BIOS shares. Jefferies Group LLC reissued a “buy” rating and set a $4.00 price objective (up from $3.00) on shares of BioScrip in a report on Thursday, August 10th. SunTrust Banks, Inc. reissued a “buy” rating and set a $3.00 price objective on shares of BioScrip in a report on Friday, November 3rd. Zacks Investment Research lowered BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday. ValuEngine lowered BioScrip from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, BidaskClub lowered BioScrip from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $3.60.

COPYRIGHT VIOLATION WARNING: “Teachers Advisors LLC Increases Holdings in BioScrip, Inc. (BIOS)” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/teachers-advisors-llc-increases-holdings-in-bioscrip-inc-bios/1692137.html.

BioScrip, Inc. (NASDAQ BIOS) opened at $2.08 on Friday. BioScrip, Inc. has a twelve month low of $0.98 and a twelve month high of $3.39. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11.

BioScrip (NASDAQ:BIOS) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). The firm had revenue of $198.70 million during the quarter, compared to analysts’ expectations of $202.91 million. During the same period in the prior year, the firm earned ($0.12) earnings per share. BioScrip’s revenue for the quarter was down 11.5% on a year-over-year basis. research analysts anticipate that BioScrip, Inc. will post -0.63 EPS for the current fiscal year.

BioScrip Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Institutional Ownership by Quarter for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.